Results 31 to 40 of about 238 (77)
Pleural mesothelioma (PM) is an aggressive cancer with a dismal prognosis. Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1, the new standard of care for PM, is still clinically unsatisfying, regardless of PM histotype.
Anichini, Andrea +29 more
core +1 more source
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? [PDF]
The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council, included a focus on the future of ...
Fox, Bernard +8 more
core +3 more sources
LBA2512 Background: In the NIBIT Foundation-sponsored phase Ib NIBIT-M4 study, we firstly showed that the hypomethylating agent (HMA) guadecitabine (guade), a prodrug of decitabine (D), followed by ipilimumab (I) was safe with promising clinical and ...
Rana, Ramiz +19 more
core +1 more source
Background: Epigenetic alterations affect virtually all cellular pathways associated with tumorigenesis and cancer progression. Importantly, the multifaceted immunomodulatory activity of DHA has been shown to improve the immunogenicity and immune ...
Diana Giannarelli +9 more
core +1 more source
Background: Glioblastoma (GBM) is the most aggressive brain tumor with dismal prognosis despite standard of care including surgery, radiotherapy, and chemotherapy.
Accolla RS +8 more
core +1 more source
MA05.07 Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBIT-MESO-1 Study [PDF]
L. Calabro' +9 more
openaire +1 more source
Background: We have previously demonstrated that cells from MHC class II-negative solid tumors can function as surrogate Antigen Presenting Cells (APCs) for their own tumor antigens, provided they optimally express MHC class II (MHC-II) molecules as a ...
Accolla RS +5 more
core
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy [PDF]
Bellone, Matteo +11 more
openaire +4 more sources
Melanoma plasticity drives immune evasion and therapy resistance through dynamic cell-state transitions beyond genetic alterations. Although epigenetic remodeling is central to this process, its impact under therapeutic pressure remains unclear.
Ceccarelli, Francesco +3 more
core +1 more source
Background Split vaccines are allowed during anticancer immunotherapy with immune-checkpoint inhibitors (CKI) and influenza vaccine is recommended in cancer patients.
Verzoni E +35 more
core

